National Academies Press: OpenBook

Scientific Standards for Studies on Modified Risk Tobacco Products (2012)

Chapter: Appendix D: Meeting Agendas

« Previous: Appendix C: Committee Biographies
Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×

Appendix D

Meeting Agendas

Thursday, February 3, 2011

Keck Center of the National Academies
500 Fifth Street, NW
Washington, DC 20001

1:00-1:15 pm

Committee Introductions and Chair’s Opening Jane Henney Committee Chair

   
1:10-1:30 pm

Charge to the Committee
Lawrence Deyton, M.D., M.S.P.H. Director Center for Tobacco Products U.S. Food and Drug Administration (FDA)

   
1:30-2:00 pm

Discussion About the Charge
Committee and FDA Representatives

   
2:00-3:00 pm

Public Comment

   
3:00 pm

Adjourn

Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×

Monday, May 9, 2011

Embassy Suites 900
Tenth Street, NW
Washington, DC 20001

9:45-10:00 am

Welcome and Introductions
Jane Henney
Committee Chair

10:00-11:30 am

Panel Discussion I: Tobacco Manufacturers Moderator: Peter Honig

   
  10:00-11:00 am: Presentations by industry representatives
11:00-11:30 am: Questions from the Committee
   
 

•   Introduction
Standards for pre-clinical studies
Mike Ogden
Senior Director of Regulatory Oversight R.J. Reynolds Tobacco Company

   
 

•   Standards for studies on in vitro models of disease
Chris Proctor
Chief Scientific Officer
British American Tobacco

   
 

•   Standards for clinical studies and biomarkers
Mohamadi Sarkar
Senior Principal Research Scientist
Altria Client Services

   
 

•   Population communication and risk perception
Lars Erik Rutqvist
Senior Vice President for Scientific Affairs Swedish Match

   
 

•   Summary J. Daniel Heck
Principal Scientist
Lorillard Tobacco Company

Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×
11:30 am- 12:00 pm Andrew Salmon
Senior Toxicologist and Chief
Air Toxicology and Risk Assessment Section
Office of Environmental Health Hazard Assessment
California Environmental Protection Agency
   
12:00-1:00 pm

Lunch

   
1:00-1:30 pm David Jacobson-Kram Associate Director of Pharmacology and Toxicology
Office of New Drugs
Food and Drug Administration
   
1:30-2:00 pm Peter G. Shields
Professor of Medicine and Oncology
Deputy Director, Lombardi Comprehensive Cancer Center
Georgetown University


Mirjana Djordjevic
Health Scientist Administrator
Tobacco Control Research Branch
National Cancer Institute
   
2:00-2:30 pm John Baron
Professor of Medicine
Dartmouth Medical School
   
2:30-2:45 pm Break
   
2:45-3:15 pm Brenda Edwards
Associate Director
Surveillance Research Program
National Cancer Institute
   
3:15-3:45 pm Ruth S. Day
Director

Medical Cognition Laboratory
Duke University
   
3:45-4:15 pm David Mendez
Associate Professor

Department of Health Management and Policy University of Michigan School of Public Health
Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×
4:15-4:30 pm

Break

4:30-6:00 pm Panel Discussion II: public health representatives
Moderator: Dan Carpenter
 

4:30-5:30 pm: Presentations by public health representatives

5:30-6:00 pm: Questions from the Committee

 

•   David Abrams
Executive Director


The Schroeder Institute for Tobacco Research and Policy Studies

Professor, Department of Health, Behavior and Society

The Johns Hopkins Bloomberg School of Public Health

 

•   Tom Glynn
Director, Cancer Science and Trends
Director, International Cancer Control
American Cancer Society

 

•   Mark Greenwold
Director, Regulatory Affairs
Campaign for Tobacco-Free Kids

 

•   Rose Marie Robertson
Chief Science Officer
American Heart Association

 

•   Mitch Zeller
Vice President for Policy and Strategic Communications
Pinney Associates

 
6:00 pm Adjourn
Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×
Page 347
Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×
Page 348
Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×
Page 349
Suggested Citation:"Appendix D: Meeting Agendas." Institute of Medicine. 2012. Scientific Standards for Studies on Modified Risk Tobacco Products. Washington, DC: The National Academies Press. doi: 10.17226/13294.
×
Page 350
Scientific Standards for Studies on Modified Risk Tobacco Products Get This Book
×
Buy Paperback | $66.00 Buy Ebook | $54.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Smoking-related diseases kill more Americans than alcohol, illegal drugs, murder and suicide combined. The passage of the Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA authority to regulate "modified risk tobacco products" (MRTPs), tobacco products that are either designed or advertised to reduce harm or the risk of tobacco-related disease. MRTPs must submit to the FDA scientific evidence to demonstrate the product has the potential to reduce tobacco related harms as compared to conventional tobacco products. The IOM identifies minimum standards for scientific studies that an applicant would need to complete to obtain an order to market the product from the FDA.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!